Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden was ...

Kidney transplant recipients with active or high risk for antibody-mediated rejection reported transplant benefits but still experienced physical restrictions and psychological concerns, according to ...

Allosite Therapeutics, a biotechnology company discovering and developing innovative integrin therapies for kidney diseases and other immunologic conditions, today announced that the company will ...

MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced that data from the Company’s transdermal GFR ...

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® ...

Reverting to pre-COVID telehealth policies could reduce access to care for kidney transplant recipients who live in ...

Unicycive Therapeutics (UNCY) announced that it will present new oxylanthanum carbonate, OLC, data at the American Society of Nephrology, ASN, ...

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese ...

Foamy urine can be a sign of kidney trouble, but it is not always serious. Research shows only a third of people with foamy ...

ASN’s Kidney Week 2025 is happening November 5-9, 2025 at the George R. Brown Convention Center in Houston, Texas.